Promising Directions in Atherosclerosis Treatment Based on Epigenetic Regulation Using MicroRNAs and Long Noncoding RNAs
Tóm tắt
Từ khóa
Tài liệu tham khảo
Maguire, 2019, Foam cell formation: A new target for fighting atherosclerosis and cardiovascular disease, Vascul. Pharmacol., 112, 54, 10.1016/j.vph.2018.08.002
Aryal, 2019, Noncoding RNA regulation of endothelial and macrophage functions during atherosclerosis, Vascul. Pharmacol., 114, 64, 10.1016/j.vph.2018.03.001
Theodorou, 2018, Endothelial cell metabolism in atherosclerosis, Front. Cell Dev. Biol., 6, 82, 10.3389/fcell.2018.00082
Alevizos, 2010, MicroRNAs as biomarkers in rheumatic diseases, Nat. Rev. Rheumatol., 6, 391, 10.1038/nrrheum.2010.81
Rana, 2007, Illuminating the silence: Understanding the structure and function of small RNAs, Nat. Rev. Mol. Cell Biol., 8, 23, 10.1038/nrm2085
Yao, 2019, Cellular functions of long noncoding RNAs, Nat. Cell Biol., 21, 542, 10.1038/s41556-019-0311-8
Rocha, 2009, Obesity, inflammation, and atherosclerosis, Nat. Rev. Cardiol., 6, 399, 10.1038/nrcardio.2009.55
Li, 2017, Function and therapeutic potential of mesenchymal stem cells in atherosclerosis, Front. Cardiovasc. Med., 4, 32, 10.3389/fcvm.2017.00032
Marais, 2019, Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease, Pathology (Phila.), 51, 165
Wang, Q., Zheng, D., Liu, J., Fang, L., and Li, Q. (2018). Atherogenic index of plasma is a novel predictor of non-alcoholic fatty liver disease in obese participants: A cross-sectional study. Lipids Health Dis., 17.
Ference, 2017, Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel, Eur. Heart J., 38, 2459, 10.1093/eurheartj/ehx144
Carr, 2019, Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment, Pathology (Phila.), 51, 148
Toth, 2016, Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease, Vasc. Health Risk Manag., 12, 171, 10.2147/VHRM.S104369
Vogt, 2017, Lipoprotein(a)-apheresis in the light of new drug developments, Atheroscler. Suppl., 30, 38, 10.1016/j.atherosclerosissup.2017.05.025
Singh, 2015, Endothelium-enriched microRNAs as diagnostic biomarkers for cardiac allograft vasculopathy, J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant., 34, 1376, 10.1016/j.healun.2015.06.008
Aryal, 2017, MicroRNAs and lipid metabolism, Curr. Opin. Lipidol., 28, 273, 10.1097/MOL.0000000000000420
Zeliadt, 2014, Big pharma shows signs of renewed interest in RNAi drugs, Nat. Med., 20, 109, 10.1038/nm0214-109
Kobayashi, 2016, RISC assembly: Coordination between small RNAs and Argonaute proteins, Biochim. Biophys. Acta, 1859, 71, 10.1016/j.bbagrm.2015.08.007
Eulalio, 2009, Deadenylation is a widespread effect of miRNA regulation, RNA, 15, 21, 10.1261/rna.1399509
Ahmadzada, 2018, Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer, Biophys. Rev., 10, 69, 10.1007/s12551-017-0392-1
Soh, 2013, MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion, Nat. Med., 19, 892, 10.1038/nm.3200
Sodi, 2017, Relationship between circulating microRNA-30c with total- and LDL-cholesterol, their circulatory transportation and effect of statins, Clin. Chim. Acta Int. J. Clin. Chem., 466, 13, 10.1016/j.cca.2016.12.031
Singh, 2018, Posttranscriptional regulation of lipid metabolism by noncoding RNAs and RNA binding proteins, Semin. Cell Dev. Biol., 81, 129, 10.1016/j.semcdb.2017.11.026
Karunakaran, 2015, Macrophage mitochondrial energy status regulates cholesterol efflux and is enhanced by anti-miR33 in atherosclerosis, Circ. Res., 117, 266, 10.1161/CIRCRESAHA.117.305624
Price, 2017, Genetic dissection of the impact of mir-33a and mir-33b during the progression of atherosclerosis, Cell Rep., 21, 1317, 10.1016/j.celrep.2017.10.023
Rayner, 2010, MiR-33 contributes to the regulation of cholesterol homeostasis, Science, 328, 1570, 10.1126/science.1189862
Goedeke, 2013, MicroRNA 33 regulates glucose metabolism, Mol. Cell. Biol., 33, 2891, 10.1128/MCB.00016-13
Goedeke, 2015, MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels, Nat. Med., 21, 1280, 10.1038/nm.3949
Akinyemiju, 2018, Epigenome-wide association study of metabolic syndrome in African-American adults, Clin. Epigenetics, 10, 49, 10.1186/s13148-018-0483-2
Christopher, 2016, MicroRNA therapeutics: Discovering novel targets and developing specific therapy, Perspect. Clin. Res., 7, 68, 10.4103/2229-3485.179431
Chai, 2018, Protective effect of Coptisine from Rhizoma Coptidis on LPS/D-GalN-induced acute liver failure in mice through up-regulating expression of miR-122, Biomed. Pharmacother. Biomedecine Pharmacother., 98, 180, 10.1016/j.biopha.2017.11.133
Willeit, 2017, Circulating MicroRNA-122 is associated with the risk of new-onset metabolic syndrome and type 2 diabetes, Diabetes, 66, 347, 10.2337/db16-0731
Willeit, 2016, Liver microRNAs: Potential mediators and biomarkers for metabolic and cardiovascular disease?, Eur. Heart J., 37, 3260, 10.1093/eurheartj/ehw146
Wang, Y.-L., and Yu, W. (2018). Association of circulating microRNA-122 with presence and severity of atherosclerotic lesions. PeerJ, 6.
Wagschal, 2015, Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis, Nat. Med., 21, 1290, 10.1038/nm.3980
Wang, 2016, Improving power and accuracy of genome-wide association studies via a multi-locus mixed linear model methodology, Sci. Rep., 6, 19444, 10.1038/srep19444
Adlakha, 2013, Pro-apoptotic miRNA-128-2 modulates ABCA1, ABCG1 and RXRα expression and cholesterol homeostasis, Cell Death Dis., 4, e780, 10.1038/cddis.2013.301
Yang, 2017, Reciprocal regulation between miR-148a/152 and DNA methyltransferase 1 is associated with hyperhomocysteinemia-accelerated atherosclerosis, DNA Cell Biol., 36, 462, 10.1089/dna.2017.3651
Naar, A.M. (2014). Methods Targeting miR-33 microRNAs for Regulating Lipid Metabolism. (8,859,519), U.S. Patent.
Fernandez-Hernando, C., and Goedeke, L. (2016). Anti-mir-27b and anti-mir-148a Oligonucleotides as Therapeutic Tools for Treating Dyslipidemias and Cardiovascular Diseases. (2016138018), U.S. Patent.
Naar, A.M., and Najafi-Shoushtari, S.H. (2012). Methods Targeting mir-128 for Regulating Cholesterol/Lipid Metabolism. (13,979,428), U.S. Patent.
Laffont, 2017, MicroRNAs in the pathobiology and therapy of atherosclerosis, Can. J. Cardiol., 33, 313, 10.1016/j.cjca.2017.01.001
Baumann, 2014, miRNA-based therapies: Strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents, Future Med. Chem., 6, 1967, 10.4155/fmc.14.116
Kota, 2010, Cancer therapy via modulation of micro RNA levels: A promising future, Drug Discov. Today, 15, 733, 10.1016/j.drudis.2010.07.003
McKiernan, 2013, Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology, Int. J. Nanomed., 8, 3907
Nguyen, D.-D., and Chang, S. (2017). Development of novel therapeutic agents by inhibition of oncogenic MicroRNAs. Int. J. Mol. Sci., 19.
Lindow, 2012, Discovering the first microRNA-targeted drug, J. Cell Biol., 199, 407, 10.1083/jcb.201208082
Loyer, 2015, MicroRNAs as therapeutic targets in atherosclerosis, Expert Opin. Ther. Targets, 19, 489, 10.1517/14728222.2014.989835
Zhang, 2017, PCSK9 as a therapeutic target for cardiovascular disease (Review), Exp. Ther. Med., 13, 810, 10.3892/etm.2017.4055
Ray, 2017, Inclisiran in patients at high cardiovascular risk with elevated ldl cholesterol, N. Engl. J. Med., 376, 1430, 10.1056/NEJMoa1615758
(2019, April 19). Evaluation of the Circulating Micro-RNA Profile Specificity in Patients with Different Stages of Atherosclerosis According to MSCT Coronary Angiography—Full Text View—ClinicalTrials.gov, Available online: https://clinicaltrials.gov/ct2/show/NCT03855891.
(2019, April 19). Inclisiran for Participants with Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol—Full Text View—ClinicalTrials.gov, Available online: https://clinicaltrials.gov/ct2/show/NCT03399370.
Lam, 2015, siRNA Versus miRNA as Therapeutics for Gene Silencing, Mol. Ther. Nucleic Acids, 4, e252, 10.1038/mtna.2015.23
Pirollo, 2008, Targeted delivery of small interfering RNA: Approaching effective cancer therapies, Cancer Res., 68, 1247, 10.1158/0008-5472.CAN-07-5810
Trang, 2011, Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice, Mol. Ther. J. Am. Soc. Gene Ther., 19, 1116, 10.1038/mt.2011.48
Nicorescu, 2019, Potential epigenetic therapeutics for atherosclerosis treatment, Atherosclerosis, 281, 189, 10.1016/j.atherosclerosis.2018.10.006
Loscalzo, 2014, Epigenetic modifications: basic mechanisms and role in cardiovascular disease (2013 Grover Conference series), Pulm. Circ., 4, 169, 10.1086/675979
Khyzha, 2017, Epigenetics of atherosclerosis: Emerging mechanisms and methods, Trends Mol. Med., 23, 332, 10.1016/j.molmed.2017.02.004
Ganesan, A. (2018). Epigenetic drug discovery: A success story for cofactor interference. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 373.
Kouzarides, 2007, Chromatin modifications and their function, Cell, 128, 693, 10.1016/j.cell.2007.02.005
Zaina, 2014, DNA methylation map of human atherosclerosis, Circ. Cardiovasc. Genet., 7, 692, 10.1161/CIRCGENETICS.113.000441
Subirana, 2017, Association between DNA methylation and coronary heart disease or other atherosclerotic events: A systematic review, Atherosclerosis, 263, 325, 10.1016/j.atherosclerosis.2017.05.022
Muka, 2016, The role of epigenetic modifications in cardiovascular disease: A systematic review, Int. J. Cardiol., 212, 174, 10.1016/j.ijcard.2016.03.062
Aavik, 2019, DNA methylation processes in atheosclerotic plaque, Atherosclerosis, 281, 168, 10.1016/j.atherosclerosis.2018.12.006
Qi, 2011, Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent, Cardiovasc. Toxicol., 11, 157, 10.1007/s12012-011-9109-z
Yu, 2016, DNMT1-PPARγ pathway in macrophages regulates chronic inflammation and atherosclerosis development in mice, Sci. Rep., 6, 30053, 10.1038/srep30053
Suzuki, 2010, Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors, Bioorg. Med. Chem. Lett., 20, 1124, 10.1016/j.bmcl.2009.12.016
Jaiswal, 2017, Clonal Hematopoiesis and risk of atherosclerotic cardiovascular disease, N. Engl. J. Med., 377, 111, 10.1056/NEJMoa1701719
Chistiakov, 2017, Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation, Int. J. Cardiol., 227, 66, 10.1016/j.ijcard.2016.11.204
Kim, 2017, Recent studies on resveratrol and its biological and pharmacological activity, EXCLI J., 16, 602
Berman, A.Y., Motechin, R.A., Wiesenfeld, M.Y., and Holz, M.K. (2017). The therapeutic potential of resveratrol: A review of clinical trials. NPJ Precis. Oncol., 1.
Raj, 2014, Potential of resveratrol in the treatment of heart failure, Life Sci., 95, 63, 10.1016/j.lfs.2013.12.011
Zhang, 2017, Acetylation enhances TET2 function in protecting against abnormal DNA methylation during oxidative stress, Mol. Cell, 65, 323, 10.1016/j.molcel.2016.12.013
Jiang, 2018, Cell-specific histone modifications in atherosclerosis (Review), Mol. Med. Rep., 18, 1215
Marks, 2009, Histone deacetylase inhibitors: Potential in cancer therapy, J. Cell. Biochem., 107, 600, 10.1002/jcb.22185
Sato, 2017, DNA Hypomethylating drugs in cancer therapy, Cold Spring Harb. Perspect. Med., 7, a026948, 10.1101/cshperspect.a026948
Culmes, 2015, Alternation of histone and DNA methylation in human atherosclerotic carotid plaques, Thromb. Haemost., 114, 390, 10.1160/TH14-10-0852
Liu, 2018, TET2: A novel epigenetic regulator and potential intervention target for atherosclerosis, DNA Cell Biol., 37, 517, 10.1089/dna.2017.4118
Nicholls, 2016, Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: Results of the phase 2b, randomized, double-blind, multicenter, ASSURE Trial, Am. J. Cardiovasc. Drugs Drugs Devices Interv., 16, 55, 10.1007/s40256-015-0146-z
Ghosh, 2017, RVX 208: A novel BET protein inhibitor, role as an inducer of apo A-I/HDL and beyond, Cardiovasc. Ther., 35, e12265, 10.1111/1755-5922.12265
Schooling, 2019, How might bromodomain and extra-terminal (BET) inhibitors operate in cardiovascular disease?, Am. J. Cardiovasc. Drugs, 19, 107, 10.1007/s40256-018-00315-3
Klein, 2018, Bromodomain protein inhibition: A novel therapeutic strategy in rheumatic diseases, RMD Open, 4, e000744, 10.1136/rmdopen-2018-000744
Mujtaba, 2007, Structure and acetyl-lysine recognition of the bromodomain, Oncogene, 26, 5521, 10.1038/sj.onc.1210618
Fujisawa, 2017, Functions of bromodomain-containing proteins and their roles in homeostasis and cancer, Nat. Rev. Mol. Cell Biol., 18, 246, 10.1038/nrm.2016.143
Zhang, 2018, Macrophage/microglial Ezh2 facilitates autoimmune inflammation through inhibition of Socs3, J. Exp. Med., 215, 1365, 10.1084/jem.20171417
McCabe, 2012, EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations, Nature, 492, 108, 10.1038/nature11606
Quax, 2016, Plaque angiogenesis and its relation to inflammation and atherosclerotic plaque destabilization, Curr. Opin. Lipidol., 27, 499, 10.1097/MOL.0000000000000339
Neele, 2017, Macrophage Kdm6b controls the pro-fibrotic transcriptome signature of foam cells, Epigenomics, 9, 383, 10.2217/epi-2016-0152
Totaro, 2007, The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing, Cell, 130, 1083, 10.1016/j.cell.2007.08.019
Hoffman, R., Benz, E.J., Silberstein, L.E., Heslop, H.E., Weitz, J.I., Anastasi, J., Salama, M.E., and Abutalib, S.A. (2018). Epigenetics and Epigenomics. Hematology, Elsevier. [7th ed.]. Chapter 2.
Mercer, 2009, Long noncoding RNAs: Insights into functions, Nat. Rev. Genet., 10, 155, 10.1038/nrg2521
(2019, April 18). Evolution and Functions of Long Noncoding RNAs—ScienceDirect. Available online: https://www.sciencedirect.com/science/article/pii/S0092867409001421.
Xu, 2018, Atherosclerosis is an Epigenetic Disease, Trends Endocrinol. Metab. TEM, 29, 739, 10.1016/j.tem.2018.04.007
Wilczynska, 2015, The complexity of miRNA-mediated repression, Cell Death Differ., 22, 22, 10.1038/cdd.2014.112
Xu, 2019, Targeting epigenetics and noncoding RNAs in atherosclerosis: From mechanisms to therapeutics, Pharmacol. Ther., 196, 15, 10.1016/j.pharmthera.2018.11.003
Zhang, 2014, The ways of action of long noncoding RNAs in cytoplasm and nucleus, Gene, 547, 1, 10.1016/j.gene.2014.06.043
Fernandes, J.C.R., Acuña, S.M., Aoki, J.I., Floeter-Winter, L.M., and Muxel, S.M. (2019). Long noncoding RNAs in the regulation of gene expression: physiology and disease. Noncoding RNA, 5.
Rong, 2017, An emerging function of circRNA-miRNAs-mRNA axis in human diseases, Oncotarget, 8, 73271, 10.18632/oncotarget.19154
Denzler, 2014, Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance, Mol. Cell, 54, 766, 10.1016/j.molcel.2014.03.045
Yan, 2017, Cis- and trans-acting lncRNAs in pluripotency and reprogramming, Curr. Opin. Genet. Dev., 46, 170, 10.1016/j.gde.2017.07.009
Beckedorff, F.C., Ayupe, A.C., Crocci-Souza, R., Amaral, M.S., Nakaya, H.I., Soltys, D.T., Menck, C.F.M., Reis, E.M., and Verjovski-Almeida, S. (2013). The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation. PLoS Genet., 9.
Yoon, 2014, Functional interactions among microRNAs and long noncoding RNAs, Semin. Cell Dev. Biol., 34, 9, 10.1016/j.semcdb.2014.05.015
Hennessy, 2017, Cardiovascular disease and long noncoding RNAs: Tools for unraveling the mystery Lnc-ing RNA and phenotype, Circ. Cardiovasc. Genet., 10, e001556, 10.1161/CIRCGENETICS.117.001556
2019, The IncRNA CHROME regulates cholesterol homeostasis, Nat. Rev. Cardiol., 16, 71, 10.1038/s41569-018-0154-1
Cannon, 2016, LXRα improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes, Diabetologia, 59, 634, 10.1007/s00125-015-3827-x
Theofilatos, 2016, Transcriptional regulation of the human Liver X receptor α gene by hepatocyte nuclear factor 4α, Biochem. Biophys. Res. Commun., 469, 573, 10.1016/j.bbrc.2015.12.031
Sallam, 2018, Transcriptional regulation of macrophage cholesterol efflux and atherogenesis by a long noncoding RNA, Nat. Med., 24, 304, 10.1038/nm.4479
Zelcer, 2006, Liver X receptors as integrators of metabolic and inflammatory signaling, J. Clin. Invest., 116, 607, 10.1172/JCI27883
Rust, 1999, Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1, Nat. Genet., 22, 352, 10.1038/11921
Li, 2015, A liver-enriched long noncoding RNA, lncLSTR, regulates systemic lipid metabolism in mice, Cell Metab., 21, 455, 10.1016/j.cmet.2015.02.004
Holdt, 2018, Long noncoding RNA ANRIL: Lnc-ing genetic variation at the chromosome 9p21 locus to molecular mechanisms of atherosclerosis, Front. Cardiovasc. Med., 5, 145, 10.3389/fcvm.2018.00145
Congrains, 2012, Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B, Atherosclerosis, 220, 449, 10.1016/j.atherosclerosis.2011.11.017
Song, 2017, Effect of circular ANRIL on the inflammatory response of vascular endothelial cells in a rat model of coronary atherosclerosis, Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol., 42, 1202, 10.1159/000478918
Holdt, L.M., Hoffmann, S., Sass, K., Langenberger, D., Scholz, M., Krohn, K., Finstermeier, K., Stahringer, A., Wilfert, W., and Beutner, F. (2013). Alu elements in ANRIL noncoding RNA at chromosome 9p21 modulate atherogenic cell functions through trans-regulation of gene networks. PLoS Genet., 9.
Chi, 2017, Long non-coding RNA ANRIL in gene regulation and its duality in atherosclerosis, J. Huazhong Univ. Sci. Technol. Med., 37, 816
Arslan, 2017, CardiolincTM network Long noncoding RNAs in the atherosclerotic plaque, Atherosclerosis, 266, 176, 10.1016/j.atherosclerosis.2017.10.012
Cremer, 2019, Hematopoietic deficiency of the long noncoding RNA MALAT1 promotes atherosclerosis and plaque inflammation, Circulation, 139, 1320, 10.1161/CIRCULATIONAHA.117.029015
Gast, 2019, Immune system-mediated atherosclerosis caused by deficiency of long noncoding RNA MALAT1 in ApoE-/-mice, Cardiovasc. Res., 115, 302, 10.1093/cvr/cvy202
Song, 2018, LncRNA MALAT1 regulates smooth muscle cell phenotype switch via activation of autophagy, Oncotarget, 9, 4411, 10.18632/oncotarget.23230
Michalik, 2014, Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth, Circ. Res., 114, 1389, 10.1161/CIRCRESAHA.114.303265
Zhang, 2018, Long noncoding RNA malat1 regulates angiogenesis in hindlimb ischemia, Int. J. Mol. Sci., 19, 1723, 10.3390/ijms19061723
Wu, 2014, LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity, Circulation, 130, 1452, 10.1161/CIRCULATIONAHA.114.011675
Forstermann, 2012, Nitric oxide synthases: Regulation and function, Eur. Heart J., 33, 829, 10.1093/eurheartj/ehr304
Ajami, 2017, Systems biology analysis of longitudinal functional response of endothelial cells to shear stress, Proc. Natl. Acad. Sci. USA, 114, 10990, 10.1073/pnas.1707517114
Miao, Y., Ajami, N.E., Huang, T.-S., Lin, F.-M., Lou, C.-H., Wang, Y.-T., Li, S., Kang, J., Munkacsi, H., and Maurya, M.R. (2018). Enhancer-associated long noncoding RNA LEENE regulates endothelial nitric oxide synthase and endothelial function. Nat. Commun., 9.
Man, 2018, Angiogenic patterning by STEEL, an endothelial-enriched long noncoding RNA, Proc. Natl. Acad. Sci. USA., 115, 2401, 10.1073/pnas.1715182115
Lyu, 2019, SENCR stabilizes vascular endothelial cell adherens junctions through interaction with CKAP4, Proc. Natl. Acad. Sci. USA, 116, 546, 10.1073/pnas.1810729116
Filice, M., and Ruiz-Cabello, J. (2019). Nucleic Acid Nanotheranostics: Biomedical Applications, Elsevier.
Hung, J., Miscianinov, V., Sluimer, J.C., Newby, D.E., and Baker, A.H. (2018). Targeting noncoding RNA in vascular biology and disease. Front. Physiol., 9.
Kole, 2012, RNA therapeutics: Beyond RNA interference and antisense oligonucleotides, Nat. Rev. Drug Discov., 11, 125, 10.1038/nrd3625
Haemmig, 2017, Targeting LncRNAs in cardiovascular disease: Options and expeditions, Circ. Res., 120, 620, 10.1161/CIRCRESAHA.116.310152
Yang, 2017, CRISPR/Cas9-mediated noncoding RNA editing in human cancers, RNA Biol., 15, 35, 10.1080/15476286.2017.1391443
Ho, 2015, Targeting noncoding RNAs with the CRISPR/Cas9 system in human cell lines, Nucleic Acids Res., 43, e17, 10.1093/nar/gku1198
Cervadoro, A., Palomba, R., Vergaro, G., Cecchi, R., Menichetti, L., Decuzzi, P., Emdin, M., and Luin, S. (2018). Targeting inflammation with nanosized drug delivery platforms in cardiovascular diseases: Immune cell modulation in atherosclerosis. Front. Bioeng. Biotechnol., 6.
Nakhlband, 2018, Combating atherosclerosis with targeted nanomedicines: Recent advances and future prospective, BioImpacts BI, 8, 59, 10.15171/bi.2018.08
Nie, 2015, Detection of atherosclerotic lesions and intimal macrophages using CD36-targeted nanovesicles, J. Control. Release Off. J. Control. Release Soc., 220, 61, 10.1016/j.jconrel.2015.10.004
Weissig, 2015, Nanopharmaceuticals (part 2): Products in the pipeline, Int. J. Nanomed., 10, 1245, 10.2147/IJN.S65526
Bobo, 2016, Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date, Pharm. Res., 33, 2373, 10.1007/s11095-016-1958-5
Sarmento, B., and das Neves, J. (2018). Translational exploration and clinical testing of silica–gold nanoparticles in development of multifunctional nanoplatform for theranostics of atherosclerosis. Biomedical Applications of Functionalized Nanomaterials, Elsevier. Chapter 23.